Abstract:Objective: The coronavirus disease (COVID-19) pandemic, resulting from human-to-human transmission of a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has caused a global health emergency. The lack of a specific drug or treatment strategy against this disease makes it devastating. Given that the main protease (Mpro) of SARS-CoV-2 plays an indispensable role in viral polyprotein processing, its successful inhibition prevents viral replication and constrains virus spread. Therefore, developing an effective SARS-CoV-2 Mpro inhibitor to treat COVID-19 is imperative. Materials and methods: We employed a high-throughput screening (HTS) method based on fluorescence polarization (FP) assay and further confirmed by the fluorescence resonance energy transfer (FRET) method for the discovery of Mpro inhibitors. Then multiple approaches were taken to investigate the inhibition profiles of the hit compounds against Mpro, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) proliferation assay, surface plasmon resonance analysis (SPR), high-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry (HPLC-Q-TOF-MS), cytopathic effect (CPE) assay, molecule docking, and the drug-likeness analysis. Results: In this study, four Mpro inhibitors with low toxicity were selected from HTS. According to SPR, all the hit compounds had medium binding affinities toward SARS-CoV-2 Mpro. HPLC-Q-TOF-MS results revealed the non-covalent linkage of each compound with SARS-CoV-2 Mpro. Molecule docking simulated the molecule interactions between each compound and the substrate binding pocket of SARS-CoV-2 Mpro. CPE assay was used to detect their inhibitory activities against coronaviruses HCoV-OC43 and HCoV-229E. In particular, the IMB63-8G compound demonstrated the highest antiviral potency [50% effective concentration (IC50) value of 1.71 μg/mL] and selectivity against HCoV-OC43 (SI = 39), which was more than 4-fold higher than that of ribavirin (RBV). Besides, the IMB63-8G compound possessed favorable drug-likeness characteristics. Conclusions: Our results will highlight the therapeutic potential of these compounds for the treatment of SARS-CoV-2 infection.

Discovery of the covalent SARS‐CoV‐2 Mpro inhibitors from antiviral herbs via integrating target‐based high‐throughput screening and chemoproteomic approaches

Discovery of potential inhibitors targeting SARS-CoV-2 Mpro

Structure-Based Discovery of the SARS-CoV-2 Main Protease Noncovalent Inhibitors from Traditional Chinese Medicine

Discovery and characterization of naturally occurring covalent inhibitors of SARS-CoV-2 Mpro from the antiviral herb Ephedra

Identification of Natural Compounds Targeting SARS-CoV-2 Mpro by Virtual Screening and Molecular Dynamics Simulations

Highly Efficient Discovery of the Covalent M Pro Inhibitors from Crude Pu-erh Tea by Integrating Biochemical and Chemoproteomic Approaches

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Discovering Potent Inhibitors Against the Mpro of the SARS-CoV-2. A Medicinal Chemistry Approach

Miniaturized Modular Click Chemistry‐enabled Rapid Discovery of Unique SARS‐CoV‐2 Mpro Inhibitors With Robust Potency and Drug‐like Profile

Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors

Discovery and characterization of the covalent SARS-CoV-2 3CL pro inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches

Structure-Based Discovery of Novel Nonpeptide Inhibitors Targeting SARS-CoV-2 M<SUP>pro</SUP>

Structure of Mpro from COVID-19 virus and discovery of its inhibitors

SARS-CoV-2 Mpro Inhibitors with Antiviral Activity in a Transgenic Mouse Model

Discovery and Characterization of the Covalent SARS-CoV-2 3clpro Inhibitors from Ginkgo Biloba Extract Via Integrating Chemoproteomic and Biochemical Approaches

Traditional herbal compounds as candidates to inhibit the SARS-CoV-2 main protease: an in silico study

Discovery of TCMs and derivatives against the main protease of SARS-CoV-2 via high throughput screening, ADMET analysis, and inhibition assay in vitro

Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies

Evaluation of natural products from virtual screenings as SARS-CoV-2 main protease inhibitors using combinational experiments

An Enhanced Hybrid Screening Approach to Identify Potent Inhibitors for the SARS-CoV-2 Main Protease From the NCI Compound Library

Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation